John R. Leone has served as a member of the Windtree Board of Directors since November 2012 and was elected Chairman in January 2013. He serves as a member of the Board’s Compensation Committee and Nomination and Governance Committee. With over 30 years of experience, Mr. Leone has built an outstanding track record in pharmaceutical operations, commercial portfolio management, and financing life science companies. Mr. Leone’s commercial experience includes significant domestic and international executive management roles and direct responsibility for the commercial launch of numerous pharmaceutical products.
Mr. Leone is currently an Operating Partner at Madryn Asset Management, an investment platform focused on providing capital to healthcare companies. Previously, Mr. Leone was a partner at Visium Asset Management LLC, an investment platform focused on health-care royalties and related revenues, from May 2013 to January 2017. Prior to joining Visium, Mr. Leone was a partner at Paul Capital Healthcare, a private equity firm that manages one of the largest dedicated global health-care funds. Previously, Mr. Leone served as President and Chief Executive Officer at Cambrex Corporation and as Senior Vice President and Chief Operating Officer of U.S. commercial operations at Aventis Pharmaceuticals. While at Aventis, he was responsible for all commercial business units, including oncology, metabolism, cardiovascular, dermatology, respiratory and anti-infective. Mr. Leone also served on the Board of Directors at ViroPharma Incorporated until its acquisition in March 2014.
Mr. Leone received his B.S. degree in Engineering from the U.S. Military Academy at West Point and his MBA from the University of Colorado.
Craig Fraser joined Windtree in February of 2016 as President and Chief Executive Officer. He was also appointed to serve as a member of the Board of Directors in February 2016.
Mr. Fraser brings over 28 years of experience as a leader in both product development and commercial operations, and in building biopharmaceutical and device businesses for both startups and larger companies. Prior to joining the company, he held executive positions at several biopharmaceutical companies, including as Chief Operating Officer at Aegerion Pharmaceuticals, Vice President of Global Disease Areas at Pfizer, Vice President and Global Business Manager at Wyeth, and Vice President of Sales & Marketing and Commercial Operations at Johnson & Johnson / Centocor. Mr. Fraser is a veteran of both the U.S. Marine Corps and the U.S. Army.
Mr. Fraser received his B.S. degree from Slippery Rock University of Pennsylvania.
Joseph M. Mahady has served as a member of the Windtree Board of Directors since January 2013. He also serves as Chairman of the Board’s Compensation Committee and a member of the Audit Committee. Mr. Mahady has extensive strategic and operational experience in the biopharmaceutical industry, and broad international commercial experience, having served in a direct leadership role in more than 30 product launches. He has a successful record of developing profitable businesses based on transformational technologies in both the U.S. and international markets.
Mr. Mahady held significant leadership positions during his 30-year career with Wyeth Corporation, including President of Wyeth Pharmaceuticals and Senior Vice President of Wyeth Corporation, with responsibility for directing the worldwide operations of Wyeth’s $20 billion global pharmaceutical business. He retired from Wyeth in 2009. Since his retirement Mr. Mahady served as a director on the boards of Albemarle, EKR Therapeutics and Strongbridge Biopharma and as Chairman of Lumara Health (formerly KV Pharmaceuticals).
Mr. Mahady received his B.S. degree in Pharmacy from St. John’s University College of Pharmacy and his MBA in Pharmaceutical Studies from Fairleigh Dickinson University.
Bruce A. Peacock has served as a member of the Windtree Board of Directors since September 2010. He also serves as Chairman of the Board’s Audit Committee and is a member of the Compensation and the Nomination and Governance Committees. Mr. Peacock brings his extensive biotech and pharmaceutical experience to the Board, including financial expertise in debt, equity capital and alliance transactions. He also has significant experience in drug development, having led the effort to gain regulatory approval for several drug candidates in the United States and in other major markets worldwide. Mr. Peacock also has held responsibility for marketing, commercial and manufacturing operations.
Mr. Peacock is a Venture Partner with SV Life Sciences Advisers LLC. He retired from Ophthotech Corporation in September 2014, where he served as Chief Financial and Business Officer, having served as Chief Business Officer. Prior to joining Ophthotech, he served as President and Chief Executive Officer and a Director and Co-Chairman of the Board of Alba Therapeutics, Chief Executive Officer and Director of The Little Clinic, a medical care services company, President and Chief Executive Officer and a Director of Adolor Corporation, a publicly-held biotechnology company, President, Chief Executive Officer and a Director of Orthovita Inc., a publicly-held orthopaedic biomaterials company, Executive Vice President, Chief Operating Officer and a Director of Cephalon Inc., and Chief Financial Officer of Centocor Inc. Mr. Peacock serves as Co-Chairman of Alba Therapeutics and as a member of the boards of directors of the biopharmaceutical companies Dicerna Pharmaceuticals, Inc. and Ocular Therapeutix. Mr. Peacock also serves on the boards of directors of Invisible Sentinel, Inc., PanOptica, Inc., and CARMA Therapeutics, all privately-owned companies.
Mr. Peacock earned a Bachelor’s degree in Business Administration from Villanova University and is a Certified Public Accountant.
Dr. Marvin E. Rosenthale has served as a member of the Windtree Board of Directors since 1998. He also serves as Chairman of the board’s Nomination and Governance Committee and member of the Audit Committee. Dr. Rosenthale brings to the board more than 50 years of management and executive experience in the pharmaceutical industry. In addition, he has served as a member of the Board of Directors of 10 pharmaceutical companies, which provides him a broad perspective of the customs, practices and strategic priorities of pharmaceutical companies in today’s challenging and competitive financial markets.
Prior to his retirement in 1999, Dr. Rosenthale served as President and Chief Executive Officer of Allergan Ligand Retinoid Therapeutics Inc., having joined as Vice President in 1993. Previously, over a period of 16 years, Dr. Rosenthale served in a variety of executive positions at Johnson & Johnson, including Vice President of Drug Discovery Worldwide at R.W. Johnson Pharmaceutical Research Institute, Director of the divisions of Pharmacology and Biological Research, and Executive Director of Drug Discovery Research at Ortho Pharmaceutical. Dr. Rosenthale also served in various positions with Wyeth Laboratories. Dr. Rosenthale has served on the Boards of Directors of NuRx Pharmaceuticals Inc. and Radient Pharmaceuticals Corp. (formerly AMDL Inc.).
Dr. Rosenthale received a Ph.D. in Pharmacology from Hahnemann Medical College, a M.Sc. in Pharmacology from Philadelphia College of Pharmacy & Science, and a B.Sc. in Pharmacy from the Philadelphia College of Pharmacy & Science.